Folia Medica Indonesiana
ISSN 0303-7932
Vol. 42 / No. 2 / Published : 2006-04
Related with : Scholar Yahoo! Bing
Original Article :
Role of mouthpiece on the efficacy and safety of budesonide turbuhaler in the treatment of asthmatic children: lesson from m3 study
Author :
- Ariyanto Harsono*1
- Department of Paediatrics Airlangga University School of Medicine Dr Soetomo Teaching Hospital Surabaya, Indonesia
Abstract :
The currently used M0 budesonide turbuhaler mouthpiece is effective and safe. The new M3 turbuhaler mouthpiece is established and expected to be as effective as M0 with lower dose of budesonide. The primary objective of the study is to compare the efficacy and safety of budesonide delivered by Pulmicort Turbuhaler M0 to that delivered by Pulmicort Turbuhaler M3 in asthmatic children, 6-17 years of age. The study start with a 14 day run-in period during which all subjects will inhale a daily dose of 200 μg from Pulmicort Turbuhaler M0 each morning and be randomized to a 12- week treatment period, to either inhale a daily dose of 720 or 180 μg from Pulmicort Turbuhaler M3, or 800 or 200 μg from Pulmicort Turbuhaler M0. Each centre has up to a 6-month period in which to randomize approximately eight subjects. Approximately 48 children will be randomized into each of the four treatment arms. Approximately 24 children from each of the two high doses, bid treatment arms will, at the time of randomization, are enrolled into each of two subset arms. The primary outcome is pulmonary function test results and adverse event. Analysis of the primary efficacy variable of change from baseline to the subject’s average % predicted FEV1 during the 12-week treatment period provided results indicating superiority of budesonide turbuhaler over placebo for each formulation (M3 or MO) and each dose, comparability between budesonide turbuhaler M3 360 mg bid and budesonide turbuhaler 400 μg bid, comparability between budesonide turbuhaler M3 180 mg qd and budesonide turbuhaler M0 200 μg qd. Investigation of subgroups and sub-populations for the primary variables of change from baseline to the subject’s average % predicted FEV1 during the 12-week treatment period indicated that treatment group differences were similar for the 6- 11 year old age groups and the 12-17 year old treatment group, as evidenced by a non significant (p=0,80) treatment by-age-group interaction term. The most frequently occurring AEs in subjects in the safety analysis set during the randomized treatment period were headache (7.8%), nasopharyngitis (7.8%), pharyngolaryngeal pain (6.2%), pyrexia (5.2%), upper respiratory tract infection (5.0%), and cough (4.8%). The incidence of each of these events was generally similar across the treatment groups. In conclusion, lower dose Budesonide with mouthpiece M3 turbuhaler, which is considered more convenient for children, is as effective and safe as M0 with higher dose in the treatment of asthmatic children and adolescents.
Keyword :
Asthmatic children, budesonide, M0, M3, efficacy, safety,
References :
L Agertoft,(1993) Importance of inhalation device on the effects of budesonide no info : Arch Dis Child
L Pedersen,(1993) Importance of inhalation device on the effects of budesonide no info : Arch Dis Child
LB Bacharier,(2004) Long-term effects of budesonide on Hypothalamic-Pituitary-adrenal axis function in children with mild to moderate asthma no info : Paediatrics
HH Raissy,(2004) Long-term effects of budesonide on Hypothalamic-Pituitary-adrenal axis function in children with mild to moderate asthma no info : Paediatrics
L Wilson,(2004) Long-term effects of budesonide on Hypothalamic-Pituitary-adrenal axis function in children with mild to moderate asthma no info : Paediatrics
B McWilliam,(2004) Long-term effects of budesonide on Hypothalamic-Pituitary-adrenal axis function in children with mild to moderate asthma no info : Paediatrics
RC Strunk,(2004) Long-term effects of budesonide on Hypothalamic-Pituitary-adrenal axis function in children
Archive Article
Cover Media | Content |
---|---|
Volume : 42 / No. : 2 / Pub. : 2006-04 |
|